col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


24 Results       Page 1

 [1] 
Wiley: Archiv der Pharmazie
  original article Date Title Authors   All Authors
1 [GO] 2026―Jan―08 Erratum: Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS-CoV-2 Mpro for Next-Generation PROTAC-Based Therapeutics
2 [GO] 2025―Dec―23 Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor Rabea Voget, Victoria Steiger, Julian Breidenbach, Katharina Sylvester, Christin Müller-Ruttloff, Chun-Chiao Yang, et al. (+4)
3 [GO] 2025―Dec―13 Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS-CoV-2 Mpro for Next-Generation PROTAC-Based Therapeutics Enrico Mario Alessandro Fassi, Nedra Mekni, Marco Albani, Sabine Maehrlein, Annabelle Carolin Weldert, Tanja Schirmeister, et al. (+2)
4 [GO] 2025―Nov―29 Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS-CoV-2 Felipe Cardoso Prado Martins, Johannes Lang, Fernanda dos Reis Rocho, Xianxian Wang, Vinícius Bonatto, Jerônimo Lameira, et al. (+2)
5 [GO] 2025―Sep―09 Synthesis and Evaluation of Thiosemicarbazone Inhibitors for SARS-CoV-2 Mpro by Spectroscopy and Microscale Thermophoresis Leyao Chen, Xinluan Lv, Xiaoyu Chang, Ruiyong Wang
6 [GO] 2025―Jan―28 Synthesis and biological investigation of peptidomimetic SARS-CoV-2 main protease inhibitors bearing quinoline-based heterocycles at P3 Sara Rossi, Graziano Deidda, Lia Fiaschi, Roberta Ibba, Mariachiara Pieroni, Maria Dichiara, et al. (+16)
7 [GO] 2024―Dec―09 Phthalimide derivatives as a new class of papain-like protease inhibitors in SARS-CoV-2 Thomas Fischer, David Frasson, Martin Sievers, Rainer Riedl
8 [GO] 2024―Nov―09 Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS-CoV-2 Virginia Fuochi, Salvatore Furnari, Giuseppe Floresta, Vincenzo Patamia, Chiara Zagni, Filippo Drago, et al. (+2)
9 [GO] 2024―Aug―16 Synthesis, in vitro and in silico evaluation of gallamide and selenogallamide derivatives as inhibitors of the SARS-CoV-2 main protease Maryelle A. G. de Carvalho, Gabriella B. Souza, Tiago Tizziani, Carime L. M. Pontes, Bibiana P. Dambrós, Natália F. de Sousa, et al. (+5)
10 [GO] 2024―Aug―06 An in-depth analysis of COVID-19 treatment: Present situation and prospects Md Ariful Islam, Kalyani Pathak, Riya Saikia, Pallab Pramanik, Aparoop Das, Prasenjit Talukdar, et al. (+4)
11 [GO] 2024―Apr―22 Spectroscopic investigation and structural simulation in human serum albumin with hydroxychloroquine/Silybum marianum and a possible potential COVID-19 drug candidate Maryam S. H. Tekyeh, Seyed M. M. Shushtarian, Alireza I. Bakhsh, Saeed H. Tackallou, Hossein Lanjanian
12 [GO] 2023―Dec―13 Combating DC-SIGN-mediated SARS-CoV-2 dissemination by glycan-mimicking polymers Jonathan Cramer, Xiaohua Jiang, Butrint Aliu, Beat Ernst
13 [GO] 2023―Oct―19 In vitro antiviral activity of favipiravir and its 6- and 3-O-substituted derivatives against coronavirus: Acetylation leads to improvement of antiviral activity Valeria Elizalde, Santiago Mirazo, Angel H. Romero, Guzman Alvarez
14 [GO] 2023―Oct―16 Exploration of 1,2,3-triazolo fused triterpenoids as inhibitors of human coronavirus 229E targeting the viral nsp15 protein Rui Wang, Annelies Stevaert, Tien Nguyen Truong, Qifei Li, Besir Krasniqi, Benjamin Van Loy, et al. (+3)
15 [GO] 2023―Oct―13 Evaluation of in vitro SARS-CoV-2 inactivation by a new quaternary ammonium compound: Bromiphen bromide Sergio Strizzi, G. Cappelletti, M. Biasin, Angelica Artasensi, Laura Fumagalli, Antonella Casiraghi
16 [GO] 2023―May―31 Inhibitory effects of 190 compounds against SARS-CoV-2 Mpro protein: Molecular docking interactions Gabriella B. Souza, Larissa Sens, Stefan J. Hammerschmidt, Natália F. de Sousa, Maryelle A. G. de Carvalho, Carlos V. D. Dos Santos, et al. (+15)
17 [GO] 2023―Jan―24 Blood pH and COVID-19 Mahmoud Fahmi Elsebai, EL-Sayed E. Habib
18 [GO] 2022―Nov―01 BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry Aurélien F. A. Moumbock, Hoai T. T. Tran, Evelyn Lamy, Stefan Günther
19 [GO] 2022―Jun―08 Ginkgo biloba in the management of the COVID-19 severity Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ajeet Kaushik, Małgorzata Kujawska, Gaber El-Saber Batiha
20 [GO] 2022―May―24 Thiazole-based SARS-CoV-2 protease (COV M pro ) inhibitors: Design, synthesis, enzyme inhibition, and molecular modeling simulations Reham W. Elsayed, Mohamed A. Sabry, Hussein I. El-Subbagh, Said M. Bayoumi, Selwan M. El-Sayed
21 [GO] 2022―Mar―04 Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2 Farak Ali, Shahnaz Alom, Anshul Shakya, Surajit K. Ghosh, Udaya P. Singh, Hans R. Bhat
22 [GO] 2022―Jan―18 A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2 Prerna Malik, Sonika Jain, Pankaj Jain, Jyoti Kumawat, Jaya Dwivedi, Dharma Kishore
23 [GO] 2021―Nov―21 Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19 Manoj Manickam, Sangeetha Meenakshisundaram, Thanigaimalai Pillaiyar
24 [GO] 2021―Aug―24 Binding of boswellic acids to functional proteins of the SARS-CoV-2 virus: Bioinformatic studies Reinhard H. Caliebe, Thomas Scior, Hermann P. T. Ammon
 [1] 

24 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.018 sec